Patients For Affordable Drugs NOW

P4ADNOW’s Executive Director, @GlobalDiaBEATes, breaks down how Big Pharma games the patent system to keep prices and profits high, and how we are working to stop patent abuse to ensure more competition in the drug market and lower drug costs. Be part of this fight because together we can win. youtube.com/watch?v=BupFd3…

Keeping up to date on the biggest news in drug pricing has never been easier with P4ADNOW's Week In Review! Published every Friday, our Week In Review rounds up the latest news and important conversations in drug pricing and delivers them straight to your inbox. Stay informed, subscribe now: mailchi.mp/654be71cbbf5/w…

Rep. Ocasio-Cortez is absolutely right, pharmaceutical monopolies and vertical integration increase costs for patients and make it harder to access care. We urgently need Congress to do more to rein in this industry and ensure patients can get the medications they need at prices they can afford.

The bipartisan Eliminating Thickets to Improve Competition (ETHIC) Act would give patients faster access to more affordable prescription drugs but Big Pharma is lobbying against it to protect their profits. Make sure they don’t get their way -- send a letter to your representative urging them to put patients first by supporting ETHIC today: tinyurl.com/3bynbf37

Drug companies point the finger at PBMs but the root of high drug prices are the high list prices set by the drug companies themselves. Learn how P4ADNOW is fighting back at PatientsForAffordableDrugsNow.org

New study examines how rising out-of-pocket healthcare costs are affecting Americans, Ozempic and Wegovy could be produced for as little as ~$3 but not in America, and the FDA is taking steps that could accelerate biosimilar entry. Read more at our Week in Review: tinyurl.com/5y4eufyu

Brand-name drug companies are manipulating the patent system to keep generics off the market. This ensures drug prices stay high while patients struggle to afford them. Learn more about patent thickets and other Big Pharma schemes at PatientsPushForCompetition.org

One patient, $24,699 in total drug costs. But because of Medicare’s out-of-pocket cap, this patient paid $2,100 for the entire year instead of tens of thousands of dollars for his medications. Without this critical reform, patients would still be exposed to devastating costs at the pharmacy counter. Reforms that cap costs and lower prices are critical for people who depend on expensive medicines.

Thank you, Rep. @AOC, for calling out how patients are ultimately getting screwed by this unjust system that's more focused on profits than patient health. We urgently need Congress to do more to rein in the drug industry and ensure patients can get the medications they need at prices they can afford.

Marge is right. Big Pharma patent abuse doesn't just affect patients, it's causing harm to families and communities and must be stopped. The ETHIC Act would reduce drug company patient abuse by addressing double patenting but Big Pharma's lobbyists are hard at work against it. Help us fight Big Pharma greed. Send a letter to your representative urging them to put patients first by supporting the ETHIC Act today: tinyurl.com/3bynbf37

Big Pharma's abuse of the patent system to keep their profits high has limited patient access to lifesaving prescription drugs for decades but the bipartisan Eliminating Thickets to Improve Competition (ETHIC) Act could change that. The ETHIC Act addresses double patenting giving patients faster access to more affordable prescription drug options. Under this bill, a generic manufacturer would only need to successfully challenge one key patent on a brand-name drug to invalidate duplicative patents. That means the low-value patents Big Pharma has relied on to block competition and keep prices artificially high would be significantly easier to defeat. Big Pharma’s army of lobbyists is working to stop common-sense reforms like the ETHIC Act. Make sure they don’t get their way -- send a letter to your representative urging them to support ETHIC today: tinyurl.com/3bynbf37

💪 Patient voices have power! Are you a patient or caregiver who has struggled with high prescription drug costs? Join our community by sharing your story today: actionnetwork.org/forms/base-sto…

The NIH, funded by the taxpayers, is a leading investor in new drug development. Yet the patients who helped fund that research are still priced out of the drugs it helped create. When pharmaceutical corporations set sky-high prices, patients get left behind. As Merith Basey put it during a conversation with @washingtonpost “We as taxpayers need a return on our investment as well.” Nine in ten Americans agree: Congress must go further to lower prescription drug prices. Because drugs don't work if patients can’t afford them.

P4AD patient advocate Jackie relies on the 2022 prescription drug law's $2,000 cap on out of pocket costs to afford the medication she needs to survive. To learn more about the 2022 prescription drug law and how it's helping patients save money at the pharmacy, visit MedicareNegotiation.org

🚫 The PERA Act would give Big Pharma even more power to block competition and keep prices high for patients. Congress must say NO to PERA and say YES to real patent reform!

In response to this evening’s State of the Union Address and President Trump’s statements on prescription drug prices, which focused primarily on TrumpRx and codifying a Most Favored Nation framework, Patients For Affordable Drugs Now CEO Merith Basey issued the following statement: “While we welcome the strong rhetoric about the urgent need to lower prescription drug prices, the reality is that nearly 50 percent of Americans are worried about their ability to afford a health care cost this year, and U.S. patients currently pay between four and eight times more than those in other high-income countries for the very same brand-name drugs. The administration has announced voluntary, direct-to-consumer and Most Favored Nation agreements, but these arrangements do not automatically lower drug prices across the entire system, nor do they apply to most high-cost or widely used medications. If Congress codifies a strong, enforceable MFN-style policy into law, it could be a meaningful step toward bringing U.S. prices in line with those paid by other high-income countries. The details will determine whether it will truly deliver lasting savings. In a system that has long favored drug corporations over patients, Americans urgently need further structural reform that permanently limits the monopoly pricing power and lowers costs at the pharmacy counter.” To read P4ADNOW's full statement, visit tinyurl.com/yern2rbc

By abusing the patent system, big drug companies keep generic and biosimilar competition off the market increasing their own profits and keeping prices high for patients. Learn how we're fighting back at PatientsPushForCompetition.org

The bipartisan Eliminating Thickets to Improve Competition (ETHIC) Act would address double patenting and give patients faster access to more affordable options. Under this bill, a generic manufacturer would only need to successfully challenge one key patent on a brand-name drug to invalidate duplicative patents. That means the low-value patents Big Pharma has relied on to block competition and keep prices artificially high would be significantly easier to defeat. Big Pharma’s army of lobbyists is working to stop common-sense reforms like the ETHIC Act. Make sure they don’t get their way -- send a letter to your representative urging them to support ETHIC today: tinyurl.com/3bynbf37

Pharmaceutical monopolies and vertical integration increase costs for patients and make it harder to access care. Thank you, Rep. @aoc, for calling out how patients are ultimately getting screwed by this unjust system that's more focused on profits than patient health.

Recent DLA Piper analysis misrepresents the importance of Medicare Negotiation, E&C Health Subcommittee Hearing, Is TrumpRx really worth the hype?, and AbbVie Files Lawsuit against Medicare Negotiation. Read more at our Week in Review: tinyurl.com/454j3tsa Get the latest updates on drug pricing reforms and patient advocacy efforts from Patients For Affordable Drugs NOW delivered straight to your inbox! Subscribe here: tinyurl.com/mubcwjd

The details about the “Most Favored Nations” agreements between the Trump Administration and 16 drug companies remain secret. When Rep. @FrankPallone asked PhRMA’s COO how patients are supposed to trust if these are good deals for Americans, her response was to just “take their word for it.” Anyone who knows pharma’s greed record knows that the American people cannot trust them.